Now Reading: ICMR Licenses SHetA2 for Early Cervical Cancer Trials
-
01
ICMR Licenses SHetA2 for Early Cervical Cancer Trials
The Indian Council of Medical Research has licensed the experimental drug SHetA2 to Emcure Pharmaceuticals for manufacturing, regulatory development and human clinical trials. Developed through research at the University of Oklahoma and…
The Story in Brief
The Indian Council of Medical Research has licensed the experimental drug SHetA2 to Emcure Pharmaceuticals for manufacturing, regulatory development and human clinical trials. Developed through research at the University of Oklahoma and evaluated by ICMR’s National Institute of Cancer Prevention and Research, SHetA2 is designed to target HPV-infected cervical cells while preserving healthy tissue.
The drug could eventually help treat high-grade precancerous lesions and early cervical cancer, reducing reliance on surgery that can affect future pregnancies. It remains unapproved for patient use. Trials must establish its safety, dosage, side effects and effectiveness against existing treatments. Researchers estimate development may take about five years. India records nearly 80,000 new cervical cancer cases and more than 42,000 deaths annually, according to the World Health Organization.
The Indian Opinion
Claims that SHetA2 has already transformed cervical cancer care are premature, while dismissing it as just another laboratory idea would also be unfair. The licensing agreement marks a practical next step, not proof of benefit. Surgery, screening and HPV vaccination remain central until trials produce reliable results. The key test will be whether SHetA2 safely matches or improves surgical outcomes without harming future fertility.
Source: timesnownews.com
This story was synthesised by AI from the source linked above.
